Antibodies, pharmaceutical compositions and methods
Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.
1. A method for inhibiting and/or reducing the proliferation of cancer cells, the method comprising administering to a subject in need thereof an effective amount of a humanized anti-SSEA-4 antibody comprising:
(a) a heavy chain region having 90% to 100% amino acid sequence homology to the amino acid sequence of SEQ ID NO: 55 and comprises three complementarity determining regions (CDRs), HCDR1, HCDR2, and HCDR3, having the amino acid sequences set forth in SEQ ID NOs: 67, 68 and 69, respectively; and
(b) a light chain region having 90% to 100% amino acid sequence homology to the amino acid sequence of SEQ ID NO: 70 and comprises three complementarity determining regions (CDRs), LCDR1, LCDR2 and LCDR3, having the amino acid sequences set forth in SEQ ID NOs: 72, 73 and 74, respectively.
2. The method of claim 1 , wherein the HCDR2 of the humanized anti-SSEA-4 antibody having at least one of the following amino acid substitutions:
(a) amino acid residue 7 from N-terminal of HCDR2 (SEQ ID NO: 68) is substituted with a neutral amino acid, and/or
(b) amino acid residue 9 from N-terminal of HCDR2 (SEQ ID NO: 68) is substituted with a neutral amino acid.
3. The method of claim 2 , wherein the amino acid residue 7 in the HCDR2 of the humanized anti-SSEA-4 antibody is substituted with a neutral amino acid selected from Serine (N56S) or Glutamine (N56Q).
4. The method of claim 2 , wherein the amino acid residue 9 in the HCDR2 of the humanized anti-SSEA-4 antibody is substituted with a neutral amino acid selected from Tyrosine (N58Y).
5. The method of claim 1 , wherein the subject is human.
6. The method of claim 1 , wherein the cancer is selected from the group consisting of breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, or brain tumor.
7. The method of claim 6 , wherein the lung cancer is tyrosine kinase inhibitor (TKI)-resistant lung cancer.
8. A method of treating cancer, the method comprising administering to a patient in need thereof an effective amount of a humanized bi-specific antibody, wherein the humanized bi-specific antibody comprises a first binding domain that specifically binds SSEA-4 of claim 1 and a second binding domain that specifically binds to T cell surface antigens.
9. The method of claim 8 , wherein the T cell surface antigens comprising CD2, CD3, CD4, CD5, CD6, CD8, CD28, CD40L or CD44.